Succinobucol 是酚类抗氧化剂，具有抗炎、抗血小板聚集活性。

Succinobucol is a novel phenolic antioxidant small molecule with anti-oxidant and anti-inflammatory properties. It designed to treat atherosclerosis of the blood vessels of the heart or coronary artery disease.

In rabbit whole blood, Succinobucol (10, 50, 100 μM) causes a dose-dependent reduction in collagen-induced platelet aggregation. Succinobucol (10, 100 μM) significantly lowers the relaxation to X/XO.

In lung metastatic breast cancer mice, Succinobucol (40 mg/kg) by tail injection significantly reduces the average number of metastatic nodules. In rats, Succinobucol (50, 100, and 150 mg/kg, i.v.) has no significant effect on either heart rate or MAP.

In the metastatic 4T1 breast cancer cells, Succinobucol, SCB and the PCD polymer (equivalent concentration to SCB) are respectively added to each well with SCB concentrations ranging from 4 ng/mL to 40 μg/mL.

Mice, injected 4T1-luc cells, are treated with Succinobucol (40 mg/kg) by tail injection every three days.

216167-82-7

C35H52O5S2

616.92

AGI-1067;Probucol monosuccinate

DMSO:162.1 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years